AI assistant
BioRestorative Therapies, Inc. — Director's Dealing 2021
Nov 22, 2021
35162_dirs_2021-11-22_2408e9d5-1d66-4491-bdd1-ca46d07ee546.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BioRestorative Therapies, Inc. (BRTX)
CIK: 0001505497
Period of Report: 2021-11-22
Reporting Person: ALSTODT LANCE (Director, President, CEO, COB)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-22 | Common Stock | P | 396 | $6.31 | Acquired | 156314 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $13.5 | 2031-03-18 | Common Stock (293479) | 293479 | Direct |
| Stock Option | $13.5 | 2031-11-04 | Common Stock (42059) | 42059 | Direct |
Footnotes
F1: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024.
F2: The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F3: The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.